Практические Рекомендации По Профилактике И Лечению Тромбоэмболических Осложнений У Онкологических Больных

Сомонова, О В; Антух, Э. А.; Долгушин, Б. И.; Елизарова, А. Л.; Сакаева, Д. Д.; Сельчук, В. Ю.; Трякин, А. А.; Cherkasov, V A

doi:10.18027/2224-5057-2020-10-3s2-47

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[14] сравнивалась эффективность и безопасность двух НМГ: эноксапарина в дозе 4 000 МЕ один раз в день ТАБЛИЦА 1. Факторы риска венозных тромбоэмболических осложнений [3] [16].…”

Section: профилактика венозных тромбоэмболических осложнений у пациен...unclassified

“…1. Пациенты с активным онкологическим заболеванием в большинстве случаев проходят комплексное лечение и подвергаются массивным хирургическим операциям, химиотерапевтическому лечению, применению антиангиогенных и гормональных препаратов, вынуждены длительно соблюдать постельный режим [3,4].…”

Section: Introductionunclassified

“…Перечень антикоагулянтов, рекомендуемых в послеоперационном периоде у пациентов с активным раком, подвергшихся хирургическому лечению[3] …”

unclassified

See 2 more Smart Citations

Modern approaches to the prevention of venous thromboembolic complications in patients with active cancer

Fedotkina

Panchenko

2023

Aterotromboz

View full text Add to dashboard Cite

Cancer is one of the most significant risk factors for venous thromboembolic complications (VTEC), which combines deep vein thrombosis and pulmonary embolism. Of the many well-known risk factors for VTEC, only cancer is associated with a 4-fold increased risk of venous thrombosis, and in cancer patients receiving chemotherapy the risk increases by up to 6.5-fold. Venous thrombosis is increasingly common in cancer patients and contributes significantly to the course of the underlying disease and mortality, especially when combined with additional risk factors, the most significant of which are surgery and chemotherapy treatment. The prevention and treatment of VTEC in cancer patients is a challenge, primarily due to the pathogenesis of cancer-associated thrombosis, the presence of additional risk factors associated with cancer, the high risk of haemorrhagic complications, reduced renal function and the recurrent nature of VTEC. Aspects of safe prevention remain an integral part of the management of patients with active cancer. The most vulnerable periods for the development of VTEC are the periods when the patient is hospitalised for surgical or therapeutic treatment and the long period of chemotherapy treatment on an outpatient basis. A comprehensive approach to the prevention of VTEC in patients with cancer should primarily involve careful selection of high-risk patients at each stage of treatment of the malignancy; these patients are the ones who will benefit most from drug thromboprophylaxis. The treatment of an already confirmed VTEC in a cancer patient always involves the additional challenges of drug interactions and increased haemorrhagic risk due to prolonged use of treatment doses of anticoagulants, which may in turn affect the effectiveness of chemotherapy or the efficiency and safety of anticoagulant therapy.

show abstract

Section: профилактика венозных тромбоэмболических осложнений у пациен...unclassified

Section: Introductionunclassified

See 1 more Smart Citation

Modern approaches to the prevention of venous thromboembolic complications in patients with active cancer

Fedotkina

Panchenko

2023

Aterotromboz

View full text Add to dashboard Cite

show abstract

“…Факт госпитализации повышает риск ВТЭО за счет снижения двигательной активности. Кроме того, существует ряд дополнительных факторов риска ВТЭО, которые должны быть учтены в конкретной клинической ситуации [28].…”

Section: риски тромбоэмболических осложнений онкологических заболеван...unclassified

Diagnostics and treatment of basic oncogynecological diseases (including those occurring during pregnancy) in the conditions of the COVID-19 pandemic. Educational and Methodological Manual

Protasova¹,

Vandeeva²,

Zazerskaya³

et al. 2020

View full text Add to dashboard Cite

show abstract

Blood coagulation system state in breast cancer patients that recovered from coronaviral infection after undergoing antitumor medical treatment

Vladimirova¹,

Frantsiyants²,

Абрамова³

et al. 2022

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

Purpose of the study. An analysis of parameters of the blood coagulation system in breast cancer patients after coronavirus disease.Materials and methods. 50 breast cancer patients were divided into groups: the main group included 30 patients after coronavirus disease, the control group 1–20 patients without confirmed COVID‑19, and control group 2–20 non-cancer women after corona‑ virus disease. All cancer patients received appropriate chemotherapy. The following parameters were studied: activated partial thromboplastin time (APTT), prothrombin time (PT), international normalized ratio (INR), prothrombin index (PTI), fibrinogen, soluble fibrin monomer complexes (SFMCs), thrombin time (TT), antithrombin III, D-dimer and plasminogen, fibrin degradation products. Blood tests were performed 4–6 weeks after the infection and two negative PCR test results for COVID‑19.Results. Patients of the main group demonstrated differences in INR values after treatment in the subgroups with asymptomatic disease (Me = 1.24) and with mild symptoms (Me = 0.97) U = 10; Z = 2.766; р = 0.0057, in subgroups with asymptomatic disease (Me = 1.24) and with moderate to severe symptoms (Me = 0.98) U = 26.5; Z = 2.199; р = 0.027, and in TT values in subgroups with asymptomatic disease (Me = 14.5) and with moderate to severe symptoms (Me = 16.5) U = 18.5; Z = –2.725; р = 0.0064. The comparison of the parameters in patients after COVID‑19 before (Me = 0.83) and after treatment (Me = 0.4) showed differences in the D-dimer values in patients with moderate to severe disease U = 6.5; Z = –2.2861; р = 0.022 towards their decrease after the therapy. Differences were found in APTT values between the main group (Me = 30.65) and control group 1 (Me = 27.85) U = 119; Z = 3.574; р = 0.00035, in antithrombin values between the main group (Me = 94) and control group 1 (Me = 106) U = 112; Z = 3.713; р = 0.00021, and in SFMCs values between the main group (Me = 17) and control group 1 (Me = 8) U = 180.5; Z = 2.356; р = 0.018.Conclusions. Determination of plasminogen levels can become an independent factor in detecting thrombotic risk in cancer patients who recovered from COVID‑19. Previous infection with COVID‑19 should be considered an additional risk factor for venous thromboembolic complications for cancer patients.

show abstract

Практические Рекомендации По Профилактике И Лечению Тромбоэмболических Осложнений У Онкологических Больных

Abstract: .

Cited by 5 publications

References 0 publications

Modern approaches to the prevention of venous thromboembolic complications in patients with active cancer

Modern approaches to the prevention of venous thromboembolic complications in patients with active cancer

Diagnostics and treatment of basic oncogynecological diseases (including those occurring during pregnancy) in the conditions of the COVID-19 pandemic. Educational and Methodological Manual

Blood coagulation system state in breast cancer patients that recovered from coronaviral infection after undergoing antitumor medical treatment

Contact Info

Product

Resources

About